Quellenangaben: Tierversuche mit Affen
1 http://www.releasechimps.org/pdfs/chimp-efficacy-paper-main.pdf, Zugriff: 03/2015
2 http://www.releasechimps.org/pdfs/chimp-efficacy-paper-main.pdf, Zugriff: 03/2015
3 http://www.safermedicines.org/pdfs/reportbiogenic.pdf, Zugriff: 03/2015
4 Ellison A., Cowey A. (2009) Differential and co-involvement of areas of the temporal and parietal streams in visual tasks. Neuropsychologia, 47(6), 169-1614. Verfügbar unter http://www.sciencedirect.com/science/article/pii/S0028393208004922, Zugriff: 03/2015
5 http://cav.asso.fr/en/parkinson.html, , Zugriff: 03/2015
6 Non-human primates in medical research and drug development_a critical review_Bailey
7 http://www.parkinson.ch/index.php?id=339, Zugriff: 03/2015
8 https://www.parkinson-web.de/content/behandlung/nebenwirkungen_der_medikamente/index_ger.html, Zugriff: 03/2015
9 http://link.springer.com/article/10.1007%2FBF00343235, Zugriff: 03/2015
10 https://www.parkinson-web.de/content/behandlung/nebenwirkungen_der_medikamente/index_ger.html, Zugriff: 03/2015
11 http://www.vitanet.de/krankheiten-symptome/morbus-parkinson/therapie/medikamente-l-dopa, Zugriff: 03/2015
12 http://cav.asso.fr/en/parkinson.html, Zugriff: 03/2015
13 http://www.leading-medicine-guide.ch/Medizinische-Fachartikel/Tiefe-Hirnstimulation-THS-bei-Parkinson-und-Tremor, Zugriff: 03/2015
14 http://www.aerzte-gegen-tierversuche.de/de/infos/kosmetik-chemikalien/97-sonstige/802-parkinsonforschung-ohne-tierleid, Zugriff: 03/2015
15 Innovation Stagnation. Challenge and Opportunity on the Critical Path to New Medical Products. U.S. Department of Health and Human Services. Food and Drug Administration (FDA) (2004). Verfügbar unter http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/UCM113411.pdf, Zugriff: 03/2015
16 Crawford, Lester M. Speech before PhRMA Annual Meeting. FDA (U.S. Food and Drug Administration) (2004). Verfügbar unter http://www.fda.gov/NewsEvents/Speeches/ucm053576.htm, Zugriff: 03/2015
17 FDA Drug Review: Postapproval Risks 1975-1985. U.S. General Accounting Office, Washington D.C. (1990). Verfügbar unter http://www.gao.gov/products/PEMD-90-15, Zugriff: 03/2015
18 Lazarou, J., Pomeranz, B. H. and Corey, P. N. (1998) Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies, J. Amer. Med. Assocn. 279, 1200– 1205. Verfügbar unter http://www.ncbi.nlm.nih.gov/pubmed/9555760, Zugriff: 03/2015
19 http://www.safermedicines.org/primates.shtml, Zugriff: 03/2015
20 http://www.safermedicines.org/primates.shtml, Zugriff: 03/2015
21 http://www.ncbi.nlm.nih.gov/pubmed/18826331, Zugriff: 03/2015
22 http://www.safermedicines.org/primates.shtml, Zugriff: 03/2015
23 http://www.safermedicines.org/pdfs/reportbiogenic.pdf, Zugriff: 03/2015
24 Schardein, J. L. (1993) Chemically Induced Birth Defects, 2nd edn. Marcel Dekker, New York. Verfügbar unter http://www.nature.com/jp/journal/v22/n8/full/7210778a.html, Zugriff: 03/2015
25 Bailey, J., Knight, A. and Balcombe, J. (2005) The future of teratology research is in vitro, Biogenic Amines,19, 97–145.Verfügbar unter http://www.animalliberationfront.com/Philosophy/Animal%20Testing/Vivisection/Jarrod%20Bailey's%20Teratology%20Study%20May%2005.pdf, Zugriff: 03/2015
26 http://www.pcrm.org/good-medicine/2005/spring/the-next-thalidomide-could-be-just-around-the, Zugriff: 03/2015
27 http://stemcells.nih.gov/info/basics/pages/basics3.aspx, Zugriff: 03/2015
28 Kleinstreuer N.C., Yang J., Berg E.L., et. Al (2014) Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms, Nature Biotechnology, 32, 583–591. Verfügbar unter http://www.nature.com/nbt/journal/v32/n6/full/nbt.2914.html, Zugriff: 03/2015
29 http://www.aerzte-gegen-tierversuche.de/de/infos/tierversuchsfreie-forschung/542-biochips-die-in-vitro-revolution-, Zugriff: 03/2015
30 http://www.navs.org.uk/about_vivisection/49/71/2522/, Zugriff: 03/2015